Epinephrine Prodrug Oral Delivery Patent Application
Summary
Aquestive Therapeutics, Inc. has filed US Patent Application US20260108458A1 covering methods of treating allergic symptoms through oral administration of epinephrine and its prodrugs, claiming pharmacokinetic parameters that are improved or comparable to intramuscular injection. The application names Stephen Paul Wargacki, Alexander Mark Schobel, and Carl Neil Kraus as inventors, with a filing date of October 23, 2025. Pharmaceutical companies developing epinephrine delivery formulations should monitor this IP filing for potential freedom-to-operate implications.
“Methods of treating an allergic symptom by oral administration of epinephrine and its prodrugs are described as having pharmacokinetic parameters that are improved or comparable to those compositions administered by intramuscular injection.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 215 changes logged to date.
What changed
USPTO published patent application US20260108458A1 assigned to Aquestive Therapeutics, covering oral epinephrine prodrug delivery methods for treating allergic symptoms. The application claims compositions with improved or comparable pharmacokinetic profiles relative to intramuscular injection. Pharmaceutical manufacturers developing epinephrine formulations for allergy treatment should monitor the prosecution of this application to assess potential freedom-to-operate concerns in the oral epinephrine delivery space.
The publication does not create immediate compliance obligations for competitors. However, companies active in the epinephrine or anaphylaxis treatment market should review their product pipelines against the claimed CPC classifications (A61K 9/006, A61K 31/05, A61K 31/11, and related prodrug formulations) to evaluate whether future products may require licensing negotiations or design-around strategies.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS OF ADMINISTERING ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS TO TREAT ALLERGY
Application US20260108458A1 Kind: A1 Apr 23, 2026
Assignee
Aquestive Therapeutics, Inc.
Inventors
Stephen Paul Wargacki, Alexander Mark Schobel, Carl Neil Kraus
Abstract
Methods of treating an allergic symptom by oral administration of epinephrine and its prodrugs are described as having pharmacokinetic parameters that are improved or comparable to those compositions administered by intramuscular injection.
CPC Classifications
A61K 9/006 A61K 31/05 A61K 31/11 A61K 31/137 A61K 31/192 A61K 31/198 A61K 31/222 A61K 31/231 A61K 31/36 A61K 31/765 A61K 36/61 A61K 47/10 A61K 47/14 A61K 47/26 A61K 47/32 A61K 47/38 A61P 37/08
Filing Date
2025-10-23
Application No.
19367129
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.